Horizon Pharma (NASDAQ:HZNP) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Thursday.

HZNP has been the topic of a number of other research reports. Mizuho raised shares of Horizon Pharma from a “neutral” rating to a “buy” rating and boosted their target price for the company from $12.00 to $18.00 in a report on Friday, January 12th. Cantor Fitzgerald set a $17.00 target price on shares of Horizon Pharma and gave the company a “buy” rating in a report on Wednesday, February 28th. Cowen reissued a “buy” rating and set a $24.00 target price on shares of Horizon Pharma in a report on Thursday, March 1st. UBS set a $20.00 target price on shares of Horizon Pharma and gave the company a “buy” rating in a report on Thursday, November 30th. Finally, ValuEngine cut shares of Horizon Pharma from a “buy” rating to a “hold” rating in a report on Sunday, December 31st. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $18.64.

How to Become a New Pot Stock Millionaire

Shares of Horizon Pharma stock opened at $14.56 on Thursday. The company has a quick ratio of 1.54, a current ratio of 1.63 and a debt-to-equity ratio of 1.91. The company has a market cap of $2,397.78, a P/E ratio of -5.78, a P/E/G ratio of 0.62 and a beta of 1.34. Horizon Pharma has a 1-year low of $9.45 and a 1-year high of $16.02.

Horizon Pharma (NASDAQ:HZNP) last issued its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $0.07. Horizon Pharma had a negative net margin of 38.87% and a positive return on equity of 18.44%. The business had revenue of $274.22 million for the quarter, compared to analysts’ expectations of $264.48 million. During the same quarter in the previous year, the firm posted $0.64 EPS. The business’s revenue for the quarter was down 11.6% compared to the same quarter last year. analysts expect that Horizon Pharma will post 1.43 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. William Blair Investment Management LLC grew its position in shares of Horizon Pharma by 12.2% during the 4th quarter. William Blair Investment Management LLC now owns 8,826,079 shares of the biopharmaceutical company’s stock valued at $128,861,000 after purchasing an additional 958,414 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Horizon Pharma by 18.6% during the 3rd quarter. Dimensional Fund Advisors LP now owns 7,433,330 shares of the biopharmaceutical company’s stock valued at $94,254,000 after purchasing an additional 1,167,722 shares in the last quarter. Brandywine Global Investment Management LLC grew its position in shares of Horizon Pharma by 3.7% during the 4th quarter. Brandywine Global Investment Management LLC now owns 4,160,474 shares of the biopharmaceutical company’s stock valued at $60,743,000 after purchasing an additional 149,854 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Horizon Pharma by 105.5% during the 4th quarter. Renaissance Technologies LLC now owns 2,279,400 shares of the biopharmaceutical company’s stock valued at $33,279,000 after purchasing an additional 1,170,000 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its position in shares of Horizon Pharma by 419.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 2,127,694 shares of the biopharmaceutical company’s stock valued at $26,979,000 after purchasing an additional 1,717,841 shares in the last quarter. Hedge funds and other institutional investors own 86.75% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/horizon-pharma-hznp-stock-rating-lowered-by-bidaskclub/1955579.html.

About Horizon Pharma

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Analyst Recommendations for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.